BioNTech at a Crossroads: FDA Filing Looms as Phase 3 Pipeline Takes Shape

The shares trade at €77 — roughly 27% below the 52-week high and below both their 50-day and 200-day moving averages. On the surface, the picture is bleak. Yet beneath the price action sit two distinct catalysts that could together rewrite the narrative: a first-ever US cancer drug application and an oncology pipeline that is now 15 phase 3 studies deep.

The most imminent catalyst is Trastuzumab Pamirtecan, an antibody-drug conjugate that BioNTech plans to submit to the FDA this year. In a phase 2 trial, the drug posted a response rate of nearly 48% in patients with endometrial cancer who had already undergone extensive prior therapy. Median progression-free survival reached 8.1 months. Critically, the drug appears to work across all HER2 expression levels — a key advantage over rival Enhertu, which is only approved for patients with the highest scores. The FDA has already granted breakthrough therapy designation, and in China the regulatory process began as early as April.

Behind that filing lies an unusually broad late-stage pipeline. BioNTech expects to launch six more phase 3 oncology studies in 2026, bringing the total to 15. Seven major data readouts are on the calendar for the year. At the ASCO conference in June, the company presented encouraging data for pumitag and gotistobart — the former showing consistent anti-tumor activity in first-line non-small cell lung cancer, the latter offering a chemo-free option for heavily pre-treated ovarian cancer patients. Meanwhile, the mRNA-based melanoma therapy BNT111 met its primary endpoint in a randomized phase 2 study, with registrational data due by year-end. And long-term follow-up from a personalized mRNA neoantigen vaccine in triple-negative breast cancer found that 11 of 14 treated patients remained relapse-free after six years — durability data that few competing platforms can match.

Should investors sell immediately? Or is it worth buying BioNTech?

The financials tell a story of transition. First-quarter revenue fell 35% year-on-year to €118.1 million, missing analyst estimates by 24%. The net loss was €531.9 million. Management confirmed its full-year revenue guidance of €2.0–2.3 billion but cautioned that 2026 will still bring no oncology revenue, as COVID vaccine sales continue their gradual decline. What provides cover is a €16.8 billion cash pile and an active $1 billion share buyback — resources that give the company years of clinical runway without existential funding pressure.

Wall Street is largely bullish, though opinions diverge on timing. Of 19 analysts covering the stock, 14 rate it a buy and none recommend selling. The consensus price target of €106.70 implies upside of more than 38%. UBS upgraded BioNTech to “Buy” after ASCO with a $135 target, and Canaccord Genuity sees fair value at $158. Bernstein is more cautious, keeping a “Market Perform” rating and a $96 target, citing execution risk in the late-stage trials.

At €77, the stock sits just 12% above its 52-week low of €68.35. The relative strength index is neutral at 45.9. This is a stock that has already discounted much of the near-term uncertainty — but not yet priced in the upside of a successful FDA filing or positive phase 3 readouts. For patient investors, the asymmetry is tangible. The question is whether the market will wait for proof or re-rate on expectation first.